All In Biotech

Drug Trial Radar · NCT06590896

Safety of Cenobamate in Japanese Subjects With Partial Onset Seizures

A Phase 2, Multicenter Open-Label Extension Study to Evaluate the Long-term Safety of Cenobamate in Japanese Subjects With Partial Onset Seizures

Last checked: Nov 19, 2026Latest source record: Jun 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Nov 4, 2022

Primary completion

Jan 31, 2027

Study completion Jan 31, 2027

Sponsor

Lead sponsor
Ono Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the long-term safety and tolerability of cenobamate in Japanese epilepsy patients with partial seizures

Conditions

  • Epilepsies, Partial

Interventions

  • CenobamateDrug

    Cenobamate will be orally administered once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidences of Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Through study completion, an average of 4 years
  2. Urinalysis(pH)Time frame: Through study completion, an average of 4 years
  3. Urinalysis(Specific Gravity)Time frame: Through study completion, an average of 4 years
  4. Urinalysis(Protein)Time frame: Through study completion, an average of 4 years
  5. Urinalysis(Glucose)Time frame: Through study completion, an average of 4 years
  6. Urinalysis(Ketone)Time frame: Through study completion, an average of 4 years
  7. Urinalysis(Bilirubin)Time frame: Through study completion, an average of 4 years
  8. Urinalysis(Blood)Time frame: Through study completion, an average of 4 years
  9. Urinalysis(Nitrite)Time frame: Through study completion, an average of 4 years
  10. Urinalysis(Urobilinogen)Time frame: Through study completion, an average of 4 years
  11. Urinalysis( Microscopic Examination)Time frame: Through study completion, an average of 4 years
  12. Liver function tests(total protein)Time frame: Through study completion, an average of 4 years
  13. Liver function tests(albumin)Time frame: Through study completion, an average of 4 years
  14. Liver function tests(total bilirubin)Time frame: Through study completion, an average of 4 years
  15. Liver function tests(aspartate transaminase)Time frame: Through study completion, an average of 4 years
  16. Liver function tests(alanine aminotransferase)Time frame: Through study completion, an average of 4 years
  17. Liver function tests(alkaline phosphatase)Time frame: Through study completion, an average of 4 years
  18. Liver function tests(gamma-glutamyl transferase)Time frame: Through study completion, an average of 4 years
  19. Hematology(Hemoglobin)Time frame: Through study completion, an average of 4 years
  20. Hematology(hematocrit)Time frame: Through study completion, an average of 4 years
  21. Hematology(white blood cell count)Time frame: Through study completion, an average of 4 years
  22. Hematology(red blood cell count)Time frame: Through study completion, an average of 4 years
  23. Hematology(mean corpuscular volume)Time frame: Through study completion, an average of 4 years
  24. Hematology(mean corpuscular hemoglobin)Time frame: Through study completion, an average of 4 years
  25. Hematology(red blood cell distribution width)Time frame: Through study completion, an average of 4 years
  26. Hematology(platelet count)Time frame: Through study completion, an average of 4 years
  27. Serum chemistry(blood urea nitrogen)Time frame: Through study completion, an average of 4 years
  28. Serum chemistry(calcium)Time frame: Through study completion, an average of 4 years
  29. Serum chemistry(chloride)Time frame: Through study completion, an average of 4 years
  30. Serum chemistry(creatinine)Time frame: Through study completion, an average of 4 years
  31. Serum chemistry(total bilirubin)Time frame: Through study completion, an average of 4 years
  32. Serum chemistry(direct bilirubin)Time frame: Through study completion, an average of 4 years
  33. Serum chemistry(alkaline phosphatase)Time frame: Through study completion, an average of 4 years
  34. Serum chemistry(alanine aminotransferase)Time frame: Through study completion, an average of 4 years
  35. Serum chemistry(gamma-glutamyl transferase)Time frame: Through study completion, an average of 4 years
  36. Serum chemistry(total protein)Time frame: Through study completion, an average of 4 years
  37. Serum chemistry(albumin)Time frame: Through study completion, an average of 4 years
  38. Serum chemistry(globulin)Time frame: Through study completion, an average of 4 years
  39. Serum chemistry(sodium)Time frame: Through study completion, an average of 4 years
  40. Serum chemistry(potassium)Time frame: Through study completion, an average of 4 years
  41. Serum chemistry(phosphorus)Time frame: Through study completion, an average of 4 years
  42. Serum chemistry(glucose)Time frame: Through study completion, an average of 4 years
  43. Heart rateTime frame: Through study completion, an average of 4 years
  44. Respiratory RateTime frame: Through study completion, an average of 4 years
  45. Blood PressureTime frame: Through study completion, an average of 4 years
  46. Electrocardiogram (ECG) FindingsTime frame: Through study completion, an average of 4 years
  47. Columbia-Suicide Severity Rating Scale (C-SSRS) ScoresTime frame: Through study completion, an average of 4 years

Locations

29 sites in 1 country. Site status is shown where the registry gives one.

  • Ehime University Hospital

    Ehime, Japan · Recruiting

  • Department of Neurology and Stroke Center, Southern Tohoku Clinic.

    Fukushima, Japan · Recruiting

  • Hiroshima University Hospital

    Hiroshima, Japan · Recruiting

  • NHO Kure Medical Center and Chugoku Cancer Center

    Hiroshima, Japan · Recruiting

  • Asahikawa Medical University Hospital

    Hokkaido, Japan · Recruiting

  • Itami City Hospital

    Hyōgo, Japan · Recruiting

  • JA-Ibaraki Tsuchiura Kyodo General Hospital

    Ibaraki, Japan · Recruiting

  • University of Tsukuba Hospital

    Ibaraki, Japan · Recruiting

  • Kagoshima University Hospital

    Kagoshima, Japan · Recruiting

  • Tanaka Neurosurgical Clinic

    Kagoshima, Japan · Recruiting

  • St. Marianna University School of Medicine Hospital

    Kanagawa, Japan · Recruiting

  • Yokohama City University Hospital

    Kanagawa, Japan · Recruiting

  • Kumamoto Ezuko Rehabilitation Medical Center

    Kumamoto, Japan · Recruiting

  • NHO Nagasaki Medical Center

    Nagasaki, Japan · Recruiting

  • Koide Clinic of Epilepsy and Neurological Disorders

    Osaka, Japan · Recruiting

  • Osaka University Hospital

    Osaka, Japan · Recruiting

  • Shintokukai Nii Neurosurgery and Psychiatry Clinic

    Osaka, Japan · Recruiting

  • Ochiai Brain Clinic

    Saitama, Japan · Recruiting

  • TMG ASAKA Medical Center

    Saitama, Japan · Recruiting

  • Sakurai Clinic

    Shiga, Japan · Recruiting

  • NHO Shizuoka Institute of Epilepsy and Neurological Disorders

    Shizuoka, Japan · Recruiting

  • Seirei Hamamatsu General Hospital

    Shizuoka, Japan · Recruiting

  • Seirei Mikatahara General Hospital

    Shizuoka, Japan · Recruiting

  • Jichi Medical University Hospital

    Tochigi, Japan · Recruiting

  • Tokushima University Hospital

    Tokushima, Japan · Recruiting

  • Medical Hospital, Tokyo Medical and Dental University

    Tokyo, Japan · Recruiting

  • National Center of Neurology and Psychiatry

    Tokyo, Japan · Recruiting

  • Tokyo Medical University Hospital

    Tokyo, Japan · Recruiting

  • NHO Yamagata National Hospital

    Yamagata, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.